Symbiotec Pharmalab

Quarterly
Consolidated
ParticularsJun '25
Revenue205.81
Expenses160.99
EBITDA60.61
EBIT50.10
Profit Before Tax44.82
Net Profit29.92
Financial Ratios
Operating Profit Margin29.83%
Net Profit Margin14.73%
Earning Per Share (Diluted)5.45
Dividends Per Share0.00